Stephen Crosier

Newcastle Upon Tyne, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Therapy and biomarker dependent progression-free survival in infant sonic hedgehog medulloblastoma: a multi-national retrospective cohort study.

Therapy and biomarker dependent progression-free survival in infant sonic hedgehog medulloblastoma: a multi-national retrospective cohort study.

Journal: EClinicalMedicine

Published: December 22, 2025

Integrated biomarker and treatment correlates of prognosis in infant non-WNT/non-SHH medulloblastoma: a multinational retrospective cohort study.

Integrated biomarker and treatment correlates of prognosis in infant non-WNT/non-SHH medulloblastoma: a multinational retrospective cohort study.

Journal: The Lancet. Child & adolescent health

Published: October 31, 2025

MYC-dependent upregulation of the de novo serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastoma.

MYC-dependent upregulation of the de novo serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastoma.

Journal: Neuro-oncology

Published: October 08, 2024

Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: A multicenter cohort study.

Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: A multicenter cohort study.

Journal: Neuro-oncology

Published: October 08, 2024

Metabolite profiles of medulloblastoma for rapid and non-invasive detection of molecular disease groups.

Metabolite profiles of medulloblastoma for rapid and non-invasive detection of molecular disease groups.

Journal: EBioMedicine

Published: August 04, 2023

Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.

Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.

Journal: Acta neuropathologica

Published: January 18, 2023

The proteomic landscape of soft tissue sarcomas.

The proteomic landscape of soft tissue sarcomas.

Journal: Nature communications

Published: August 11, 2022

Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development.

Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development.

Journal: Acta neuropathologica

Published: March 16, 2022

Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar development.

Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar development.

Journal: Cell reports

Published: July 26, 2021

Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse.

Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse.

Journal: Neuro-oncology

Published: July 17, 2021

Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnostics.

Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnostics.

Journal: Neuropathology and applied neurobiology

Published: September 21, 2020

Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study.

Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study.

Journal: The Lancet. Child & adolescent health

Published: May 11, 2020

Showing 1-12 of 20

Last Updated: 09/26/2026